Grant: Fellowship - PA: Eileen Iwanicki Fellowships in Breast Cancer Research
Direct Payment
$75,000.00
A novel small animal model to test on-target off-tumour cytotoxicity of affinity tuned anti-Her2 CAR T cells.
FY 2015-16
Summary
Chimeric antigen receptor T cell (CART) therapy has emerged as an effective treatment for blood cancers and it is currently being developed to treat solid tumour cancers such as breast cancer. A key aspect of the anti-tumour effectiveness of CART therapy is its ability to specifically kill malignant cells by recognizing cell surface proteins (ie. antigens). Her2 is a promising target antigen for CART therapy as it is found in 25% of breast cancers and has been targeted effectively by other therapies, such as Trastuzamab (Herceptin). However, CARTs can have autoimmune toxicity since tumour antigens can be found in healthy tissue at lower levels. For example, Her2 CART therapy in a patient with colorectal cancer caused off-tumour targeting of their cardiopulmonary system that eventually contributed to the patient's death. We propose to develop a mouse model that can test the on-tumour and off-tumour effects of CARTs and therefore, improve the safety profile of immune therapies.
Our first aim is to generate a mouse model that contains human Her2 antigen expression in mouse livers by delivering the gene in a Her2-carrying virus. Our second aim is to test if changing the antigen binding strength (ie. affinity) of a CAR can increase the safety of CARTs by directing them to kill only cells with high Her2 expression as seen in certain types of breast cancers. Specifically, we will test high (4D5) and low (4D5-5) affinity Her2 CARTs in mice that contain Her2 at low levels in the liver and Her2 at high levels in tumours. We expect that the low-affinity anti-Her2 CAR (4D5-5) T cells will target the Her2-high tumour cells and cause tumour regression while preserving function in the Her2-low liver. If so, then we will have shown that our pre-clinical mouse model can be used to identify on-target off-tumour CAR T cell toxicity, which will aid in improving the safety profile and clinical outcomes of future CAR T cell therapies.
Department
Program
Fellowship - PA: Eileen Iwanicki Fellowships in Breast Cancer Research
Recipient
Location
Pennsylvania, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
340010
Name
Castellarin Mauro L
Region
Pennsylvania
Country
United States of America
Orgtype
Research Institution
Partnername
Breast Cancer Society of Canada (North Sarnia, ON)
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
A novel small animal model to test on-target off-tumour cytotoxicity of affinity tuned anti-Her2 CAR T cells.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$75,000
Cihrequipment2
$0
Programname2
Fellowship - PA: Eileen Iwanicki Fellowships in Breast Cancer Research
Keyworddelim
Adoptive Cell Therapy; Animal Model; Cancer Immunotherapy; Chimeric Antigen Receptors; Safety; Toxicity
Abstract
Chimeric antigen receptor T cell (CART) therapy has emerged as an effective treatment for blood cancers and it is currently being developed to treat solid tumour cancers such as breast cancer. A key aspect of the anti-tumour effectiveness of CART therapy is its ability to specifically kill malignant cells by recognizing cell surface proteins (ie. antigens). Her2 is a promising target antigen for CART therapy as it is found in 25% of breast cancers and has been targeted effectively by other therapies, such as Trastuzamab (Herceptin). However, CARTs can have autoimmune toxicity since tumour antigens can be found in healthy tissue at lower levels. For example, Her2 CART therapy in a patient with colorectal cancer caused off-tumour targeting of their cardiopulmonary system that eventually contributed to the patient's death. We propose to develop a mouse model that can test the on-tumour and off-tumour effects of CARTs and therefore, improve the safety profile of immune therapies.
Our first aim is to generate a mouse model that contains human Her2 antigen expression in mouse livers by delivering the gene in a Her2-carrying virus. Our second aim is to test if changing the antigen binding strength (ie. affinity) of a CAR can increase the safety of CARTs by directing them to kill only cells with high Her2 expression as seen in certain types of breast cancers. Specifically, we will test high (4D5) and low (4D5-5) affinity Her2 CARTs in mice that contain Her2 at low levels in the liver and Her2 at high levels in tumours. We expect that the low-affinity anti-Her2 CAR (4D5-5) T cells will target the Her2-high tumour cells and cause tumour regression while preserving function in the Her2-low liver. If so, then we will have shown that our pre-clinical mouse model can be used to identify on-target off-tumour CAR T cell toxicity, which will aid in improving the safety profile and clinical outcomes of future CAR T cell therapies.
Competitiondate
201511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Castellarin, Mauro L
Approvedterm
3 ans 0 mois
Cihrcontribution2
Breast Cancer Initiative~ $75,000~ $0~